Inflammatory factors contribute to depression and its comorbid conditions

Science Signaling

Volumn 5, Issue 244, 2012, Pages

  Anisman, Hymie ^a   Hayley, Shawn ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR;

AUTOIMMUNE DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC STRESS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; HEART DISEASE; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COMORBIDITY; CYTOKINES; DEPRESSIVE DISORDER; DIABETES MELLITUS; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; HEART DISEASES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MODELS, BIOLOGICAL; MODELS, PSYCHOLOGICAL; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867122242     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003579     Document Type: Review

References (35)

1. H. Anisman, Z. Merali, S. Hayley, Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 85, 1-74 (2008).
2. C. L. Raison, A. H. Miller, Is depression an infl ammatory disorder? Curr. Psychiatry Rep. 13, 467-475 (2011).
3. A. Reichenberg, R. Yirmiya, A. Schuld, T. Kraus, M. Haack, A. Morag, T. Pollmächer, Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58, 445-452 (2001).
4. T. K. Inagaki, K. A. Muscatell, M. R. Irwin, S. W. Cole, N. I. Eisenberger, Inflammation selectively enhances amygdala activity to socially threatening images. Neuroimage 59, 3222-3226 (2012).
5. C. L. Raison, L. Capuron, A. H. Miller, Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 27, 24-31 (2006).
6. S. Akhondzadeh, S. Jafari, F. Raisi, A. A. Nasehi, A. Ghoreishi, B. Salehi, S. Mohebbi-Rasa, M. Raznahan, A. Kamalipour, Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress. Anxiety 26, 607-611 (2009).
7. K. Kamm, W. Vanderkolk, C. Lawrence, M. Jonker, A. T. Davis, The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J. Trauma 60, 152-157 (2006).
8. J. Gibb, S. Hayley, M. O. Poulter, H. Anisman, Effects of stressors and immune activating agents on peripheral and central cytokines in mouse strains that differ in stressor responsivity. Brain Behav. Immun. 25, 468-482 (2011).
9. M. C. Pascoe, S. G. Crewther, L. M. Carey, D. P. Crewther, Inflammation and depression: Why poststroke depression may be the norm and not the exception. Int. J. Stroke 6, 128-135 (2011).
10. T. K. Craft, A. C. DeVries, Role of IL-1 in post-stroke depressive-like behavior in mice. Biol. Psychiatry 60, 812-818 (2006).
11. S. F. Maier, L. R. Watkins, Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 695, 279-282 (1995).
12. H. Anisman, M. O. Poulter, R. Gandhi, Z. Merali, S. Hayley, Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J. Neuroimmunol. 186, 45-53 (2007).
13. N. I. Eisenberger, T. K. Inagaki, L. T. Rameson, N. M. Mashal, M. R. Irwin, An fMRI study of cytokine-induced depressed mood and social pain: The role of sex differences. Neuroimage 47, 881-890 (2009).
14. R. Dantzer, J. C. O'Connor, M. A. Lawson, K. W. Kelley, Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology 36, 426-436 (2011).
15. M. Maes, B. E. Leonard, A. M. Myint, M. Kubera, R. Verkerk, The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 702-721 (2011).
16. G. Spalletta, P. Bossù, A. Ciaramella, P. Bria, C. Caltagirone, R. G. Robinson, The etiology of poststroke depression: A review of the literature and a new hypothesis involving inflammatory cytokines. Mol. Psychiatry 11, 984-991 (2006).
17. R. S. Duman, L. M. Monteggia, A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116-1127 (2006).
18. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, N. Weisstaub, J. Lee, R. Duman, O. Arancio, C. Belzung, R. Hen, Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
19. T. Frodl, A. Carballedo, M. M. Hughes, K. Saleh, A. Fagan, N. Skokauskas, D. M. McLoughlin, J. Meaney, V. O'Keane, T. J. Connor, Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: High IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl. Psychiatry 2, e88 (2012).
20. M. Fuchikami, S. Morinobu, M. Segawa, Y. Okamoto, S. Yamawaki, N. Ozaki, T. Inoue, I. Kusumi, T. Koyama, K. Tsuchiyama, T. Terao, DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS ONE 6, e23881 (2011).
21. R. Yirmiya, I. Goshen, Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181-213 (2011).
22. T. Yoshida, T. Shiroshima, S. J. Lee, M. Yasumura, T. Uemura, X. Chen, Y. Iwakura, M. Mishina, Interleukin- 1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule. J. Neurosci. 32, 2588-2600 (2012).
23. N. DiazGranados, L. A. Ibrahim, N. E. Brutsche, R. Ameli, I. D. Henter, D. A. Luckenbaugh, R. Machado-Vieira, C. A. Zarate Jr., Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71, 1605-1611 (2010).
24. R. S. Duman, N. Li, R. J. Liu, V. Duric, G. Aghajanian, Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62, 35-41 (2012).
25. S. T. Bland, M. J. Schmid, B. N. Greenwood, L. R. Watkins, S. F. Maier, Behavioral control of the stressor modulates stress-induced changes in neurogenesis and fibroblast growth factor-2. Neuroreport 17, 593-597 (2006).
26. S. J. Evans, P. V. Choudary, C. R. Neal, J. Z. Li, M. P. Vawter, H. Tomita, J. F. Lopez, R. C. Thompson, F. Meng, J. D. Stead, D. M. Walsh, R. M. Myers, W. E. Bunney, S. J. Watson, E. G. Jones, H. Akil, Dysregulation of the fibroblast growth factor system in major depression. Proc. Natl. Acad. Sci. U.S.A. 101, 15506-15511 (2004).
27. M. Elsayed, M. Banasr, V. Duric, N. M. Fournier, P. Licznerski, R. S. Duman, Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol. Psychiatry 72, 258-265 (2012).
28. K. M. Edwards, J. A. Bosch, C. G. Engeland, J. T. Cacioppo, P. T. Marucha, Elevated macrophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav. Immun. 24, 1202-1208 (2010).
29. L. M. Christian, A. Franco, J. D. Iams, J. Sheridan, R. Glaser, Depressive symptoms predict exaggerated inflammatory responses to an in vivo immune challenge among pregnant women. Brain Behav. Immun. 24, 49-53 (2010).
30. L. Conboy, E. Varea, J. E. Castro, H. Sakouhi- Ouertatani, T. Calandra, H. A. Lashuel, C. Sandi, Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol. Psychiatry 16, 533-547 (2011).
31. H. Y. Moon, S. H. Kim, Y. R. Yang, P. Song, H. S. Yu, H. G. Park, O. Hwang, W. Lee-Kwon, J. K. Seo, D. Hwang, J. H. Choi, R. Bucala, S. H. Ryu, Y. S. Kim, P. G. Suh, Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc. Natl. Acad. Sci. U.S.A. 109, 13094-13099 (2012).
32. M. Mengozzi, I. Cervellini, P. Villa, Z. Erbayraktar, N. Gökmen, O. Yilmaz, S. Erbayraktar, M. Manohasandra, P. Van Hummelen, P. Vandenabeele, Y. Chernajovsky, A. Annenkov, P. Ghezzi, Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc. Natl. Acad. Sci. U.S.A. 109, 9617-9622 (2012).
33. K. W. Miskowiak, M. Vinberg, C. J. Harmer, H. Ehrenreich, L. V. Kessing, Erythropoietin: A candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl.) 219, 687-698 (2012).
34. X. Y. Yu, H. M. Chen, J. L. Liang, Q. X. Lin, H. H. Tan, Y. H. Fu, X. Y. Liu, Z. X. Shan, X. H. Li, H. Z. Yang, M. Yang, Y. Li, S. G. Lin, Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS ONE 6, e16239 (2011).
35. C. Herder, J. Baumert, A. Zierer, M. Roden, C. Meisinger, M. Karakas, L. Chambless, W. Rathmann, A. Peters, W. Koenig, B. Thorand, Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS ONE 6, e19852 (2011).